Equally, combination approaches in HPV-negative tumours could make simultaneous use of EGFR inhibitors (Cetuximab), MET inhibitors (Ficlatuzumab) and p53-targetted therapies be it adenoviral p53 gene therapy or use of small molecules to restore TP53 function or disrupt inactivation of wild-type p53. This evidence concerns the gene TP53 and neoplasm.